Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1089
Peer-review started: April 13, 2020
First decision: June 18, 2020
Revised: August 11, 2020
Accepted: September 3, 2020
Article in press: September 3, 2020
Published online: November 27, 2020
Processing time: 224 Days and 22.3 Hours
Routine preoperative radiotherapy (3 times 3.5 Gray) to prevent the occurrence of seeding metastases was used in our tertiary center for 28 years in patients undergoing resection for perihilar cholangiocarcinoma.
Previous research from our department showed that seeding metastases occurred in up to 20% of the patients undergoing resection of perihilar cholangiocarcinoma.
To investigate the occurrence of seeding metastases among patients with resectable perihilar cholangiocarcinoma.
A retrospective study was conducted, including all patients undergoing resection of perihilar cholangiocarcinoma in a larger tertiary center between 2000 and March 2019.
Seeding metastases occurred in 2 out of 171 patients (1.2%) undergoing resection for perihilar cholangiocarcinoma. These seeding metastases occurred at the laparotomy scar in both patients, after 17 and 21 mo, respectively. Intraoperative bile cytology showed no significant difference in the presence of tumor cells in the bile of patients undergoing preoperative radiotherapy or not.
The incidence of seeding metastases in patients with resected perihilar cholangiocarcinoma has decreased. Evidence of a potential benefit of preoperative radiotherapy could not be delivered and therefore preoperative radiotherapy in patients with resectable perihilar cholangiocarcinoma has been discontinued in our institution.
As we are the only center reporting on the use of low-dose radiotherapy to prevent seeding metastases in patients with perihilar cholangiocarcinoma, it is unlikely that other reports on this topic will appear and future research may focus more on the potential of stereotactic body radiation therapy to treat patients with unresectable perihilar cholangiocarcinoma.